Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Immutep received an A$856,669 cash rebate under Australia’s R&D tax incentive for FY2025 and plans to use it for efti and IMP761. The company says its expected cash reach extends into H1 CY2028.Material DetailsContext by AI AnalystThis is a routine but helpful funding update for a late-stage biotec…
SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that it received an A$856,669 cash rebate from the Australian Federal Government’…
Immutep received an A$ 856,669 cash rebate under Australia’s R&D tax incentive program for eligible 2025 fiscal-year spending; AusIndustry cleared an Advance overseas finding, extending eligibility to certain overseas R&D activities. Funds support R&D for efti and IMP761, with cash runway expected into the first half o